Recently added
This page was added on 04 June 2018.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Sponsor
GlaxoSmithKline Australia
Administration route
Intramuscular injection
Subcutaneous injection
Vaccine group
Combination vaccines
Description:
Registered for use in people aged ≥9 months.
MMRV — measles-mumps-rubella-varicella combination vaccine
Lyophilised pellet in a monodose vial with a pre-filled diluent syringe.
Each 0.5 mL reconstituted dose contains:
- ≥103.0 cell culture infectious dose 50% (CCID50) of live attenuated measles virus (Schwarz strain)
- ≥104.4 CCID50 of live attenuated mumps virus (RIT 4385 strain, derived from the Jeryl Lynn strain)
- ≥103.0 CCID50 of live attenuated rubella virus (Wistar RA 27/3 strain)
- ≥103.3 plaque-forming units of live attenuated varicella-zoster virus (Oka strain)
- lactose
- neomycin
- sorbitol
- mannitol
For Product Information and Consumer Medicine Information about Priorix-tetra visit the Therapeutic Goods Administration website.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.
Page history
Last updated
Last reviewed
Related diseases